What are the side effects of Naxitamab injection?

The safety of naxitamab injection (Naxitamab) in combination with GM-CSF was evaluated in patients with refractory or relapsed high-risk bone or myeloid neuroblastoma who experienced partial response, minor response, or stable disease after first or subsequent treatment, and in patients with a second complete response from two open-label, single-arm studies. During the first week of each cycle, patients received 9 mg/kg/cycle noxituzumab injection, followed by three intravenous infusions of 3 mg/kg (days 1, 3, and 5). Patients also received 250 g/m2/day subcutaneous injection of GM-CSF on days 4 to 0, and 500 g/m2/day subcutaneous injection of GM-CSF on days 1 to 5.

In clinical studies of nocetuzumab injection , the most common adverse reactions (≥25% in both studies) were infusion-related reactions, pain, tachycardia, vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, pyrexia, headache, injection site reactions, edema, anxiety, local edema, and irritability. The most common grade 3 or 4 laboratory abnormalities (≥5% in any study) were lymphopenia, neutropenia, hemoglobin decrease, platelet count decrease, potassium decrease, alanine aminotransferase increase, glucose decrease, calcium decrease, albumin decrease, sodium decrease, and phosphate decrease.

It is understood that noxituzumab injection has been approved in China, but it has not been included in medical insurance. Its price is still unclear and the purchase method is difficult. The original drug of Naxituzumab injection marketed overseas is very expensive, and the price may fluctuate due to exchange rates. For more drug information and specific prices, please consult a medical consultant.